Methods of supporting gastrointestinal homeostasis

Patent metadata

Field	Value
Publication number	US-12251391-B2
Application number	US-201917291481-A
Country	US
Kind code	B2
Filing date	Nov 8, 2019
Priority date	Nov 8, 2018
Publication date	Mar 18, 2025
Grant date	Mar 18, 2025

Abstract

The present disclosure relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to prevent or treat dysfunctions in a gastrointestinal barrier. The present disclosure further relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to prevent or treat infections.

First claim

What is claimed is:

1. A method of treating a gastrointestinal barrier dysfunction or decreasing the permeability of a gastrointestinal barrier, in an animal in need thereof, the method comprising: administering a nutritional composition that comprises a base nutritional composition and a synthetic oligosaccharide preparation to said animal, the synthetic oligosaccharide preparation comprising at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n (DP1 to DPn fractions), wherein n is an integer greater than 3; and wherein each of a DP1 and DP2 fraction independently comprises from about 0.5% to about 15% of anhydro-subunit containing oligosaccharides by relative abundance as determined by mass spectrometry, wherein said anhydro-subunit containing oligosaccharides are selected from the group consisting of anhydro-glucose, anhydro-galactose, anhydro-mannose and anhydro-fructose, to thereby treat said gastrointestinal barrier dysfunction or decrease the permeability of said gastrointestinal barrier.

2. The method of claim 1 , wherein permeability of a gastrointestinal barrier of said animal is decreased relative to permeability of said gastrointestinal barrier of said animal prior to said administering said synthetic oligosaccharide preparation.

3. The method of claim 2 , wherein said decrease is at least about a 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, or 30% decrease relative to said permeability of said gastrointestinal barrier of said animal prior to said administering said synthetic oligosaccharide preparation.

4. The method of claim 3 , wherein said permeability of said gastrointestinal barrier is determined from a blood, fecal, or urine sample from said animal.

5. The method of claim 4 , wherein said permeability is measured by determining a level of at least one microbial species in said blood, fecal, or urine sample.

6. The method of claim 4 , wherein said decrease permeability of said gastrointestinal barrier is mediated indirectly by said synthetic oligosaccharide preparation.

7. The method of claim 1 , wherein at least one symptom associated with said gastrointestinal barrier dysfunction is ameliorated.

8. The method of claim 1 , wherein said gastrointestinal barrier dysfunction is associated with or caused by an infection.

9. A method of treating an infection in an animal in need thereof, the method comprising: administering a nutritional composition comprising a base nutritional composition and a synthetic oligosaccharide preparation to said animal, the synthetic oligosaccharide preparation comprising at least n fractions of oligosaccharides each having a distinct degree of polymerization selected from 1 to n (DP1 to DPn fractions), wherein n is an integer greater than 3; and wherein each of a DP1 and DP2 fraction independently comprises from about 0.5% to about 15% of anhydro-subunit containing oligosaccharides by relative abundance as determined by mass spectrometry, wherein said anhydro-subunit containing oligosaccharides are selected from the group consisting of anhydro-glucose, anhydro-galactose, anhydro-mannose and anhydro-fructose, to thereby treat said infection.

10. The method of claim 9 , wherein a level of at least one immune cell in a sample from said animal is increased relative to a level of said at least one immune cell in a sample from said animal prior to administration of said nutritional composition that comprises said synthetic oligosaccharide preparation.

11. The method of claim 10 , wherein said increase is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% increased relative to said level of said at least one immune cell prior to administration of said nutritional composition comprising said synthetic oligosaccharide preparation.

12. The method of claim 11 , wherein a level of at least one pro-inflammatory cytokine in a sample from said animal is increased relative to a level of said at least one pro-inflammatory cytokine in a sample from said animal prior to administration of said nutritional composition that comprises said synthetic oligosaccharide preparation.

13. The method of claim 12 , wherein permeability of a gastrointestinal barrier of said animal is decreased relative to permeability of said gastrointestinal barrier of said animal prior to said administering said synthetic oligosaccharide preparation.

Assignees

• Dsm Ip Assets Bv

Inventors

• Blokker Britta
• Duval Stephane
• Geremia John Michael
• Perez Calvo Estefania
• Richard Nathalie
• Schmeisser Jerome
• Seifert Nicole
• Verlhac Viviane

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A23K50/75 Primary

  for poultry · CPC title

• A23K50/30

  for swines · CPC title